Arbutus就新冠疫苗LNP专利在加拿大及欧洲起诉辉瑞/BioNTech

智通财经
Jul 16
【Arbutus就新冠疫苗LNP专利在加拿大及欧洲起诉辉瑞/BioNTech】7月16日,Arbutus Biopharma宣布,联合独家授权方Genevant在加拿大及欧洲统一专利法院对辉瑞及BioNTech提起三项专利侵权诉讼,指控其mRNA新冠疫苗侵犯脂质纳米颗粒技术专利,寻求永久禁令及经济赔偿。公司称,此举是在美国新泽西法院诉讼基础上进一步扩大维权范围。Arbutus同时宣布,已于7月8日收到莫德纳专利侵权和解协议项下约1.78亿美元首笔非或有付款分成,并预计第三季度获得Genevant母公司股息。公司计划自第三季度起通过要约回购、公开市场回购等方式向股东返还最多约2.3亿美元资本。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10